Acquisition - February 25, 2020
AstraZeneca divests global rights to Movantik to RedHill Biopharma
AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC). “This divestment supports our strategy to realise value from medicines in our portfolio that are mature or outside our current scope […]
Collaboration - February 19, 2020
AstraZeneca and IBM collaborate in order to strengthen digital health expertise
AstraZeneca’s BioVentureHub has entered into a new collaboration with IBM Sweden. The collaboration gives small and mid-sized companies connected to IBM Sweden or AstraZeneca’s BioVentureHub access to each others’ open platforms for innovation. The collaboration aims to stimulate growth of small and mid-sized companies, to support knowledge exchange between life sciences and digital technology, and […]
In a new job - February 7, 2020
She is the new Head of AstraZeneca’s Nordic-Baltics marketing
Anna-Lena Engwall has been appointed head of AstraZeneca’s Nordic-Baltics marketing company and she started her new position February 6 2020. Anna Lena Engwall has long experience from the pharma and biotech industry and she has held a number of different managing positions at companies like Novartis and Shire. She has also been a member of […]
Clinical Trials - January 27, 2020
AstraZeneca’s Phase II DESTINY-Gastric01 trial met primary endpoint
The AstraZeneca trial met primary endpoint of objective response rate and key secondary endpoint of overall survival in patients with previously treated HER2-positive metastatic gastric cancer. Results from the positive registrational Phase II trial DESTINY-Gastric01 showed AstraZeneca’s and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan), achieved a statistically significant and clinically meaningful improvement […]
Clinical Trials - January 27, 2020
AstraZeneca’s Brilinta met primary endpoint
Brilinta reduced the risk of the composite of stroke and death after an acute ischaemic stroke or transient ischaemic attack. Results from the Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with aspirin for 30 days, reached a statistically significant and clinically meaningful reduction in the risk of the […]
Agreement - January 27, 2020
AstraZeneca to recover the global rights to brazikumab
AstraZeneca will recover the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting IL23, from Allergan. Brazikumab is currently in a Phase IIb/III programme in Crohn’s disease (CD) and a Phase IIb trial in ulcerative colitis (UC). Expected to complete in the first quarter of 2020 AstraZeneca and Allergan will terminate their existing license agreement and […]
